中国医院用药评价与分析2023，Vol.23Issue(12)：1508-1511,4.DOI:10.14009/j.issn.1672-2124.2023.12.020
203例使用奈玛特韦/利托那韦患者的联合用药情况分析
Analysis of the Combination in 203 Patients Treated with Nematavir/Ritonavir
摘要
Abstract
OBJECTIVE:To analyze the combination in patients treated with the novel antiviral drug nirmatrelvir/ritonavir,and to explore the key points of clinical pharmaceutical care of nirmatrelvir/ritonavir.METHODS:General information and drug use of 203 patients with nirmatrelvir/ritonavir in the hospital from Dec.2022 to Feb.2023 were analyzed,and the key points of pharmaceutical care were discussed from the aspects of adverse drug reactions,drug interactions and the combined application of Chinese and Western medicines.RESULTS:Among the 203 patients treated with nirmatrelvir/ritonavir,110 patients were treated with Western medicines interacting with nirmatrelvir/ritonavie,129 patients additionally received Chinese patent medicines,and 64 patients received combination therapy of Western and Chinese patent medicines.Among the patients with drug combination,18 cases had adverse drug reactions,including 9 cases of nirmatrelvir/ritonavir combined with atorvastatin,showing abnormal liver enzymes,6 cases of which were combined with Chinese patent medicines.Abnormal blood potassium levels were observed in 4 cases of nirmatrelvir/ritonavir combined with tolvaptan,2 of which were combined with Chinese patent medicines.CONCLUSIONS:Nirmatrelvir/ritonavir interacts with a variety of drugs and may increase the risk of adverse drug reactions when applied in combination.Combination therapy with Chinese and Western medicines requires an overall assessment of drug interactions,individualized adjustment of treatment regimens,and enhanced pharmacological monitoring.关键词
奈玛特韦/利托那韦/药物相互作用/药学监护/不良反应Key words
Nirmatrelvir/ritonavir/Drug interactions/Pharmaceutical care/Adverse drug reactions分类
医药卫生引用本文复制引用
蔡泓敏,朱红,陆红柳,张楠,闫阔,杨啸白,李桃园..203例使用奈玛特韦/利托那韦患者的联合用药情况分析[J].中国医院用药评价与分析,2023,23(12):1508-1511,4.基金项目
首都临床特色应用研究项目(No.Z181100001718125) （No.Z181100001718125）
